Sorry, you need to enable JavaScript to visit this website.

    Pfizer and Eisai Continue Aricept Collaboration

    Companies also enter into new collaboration to co-promote Lyrica in Japan

    (BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) today announced that its agreement with Eisai to provide Aricept to patients suffering from Alzheimer’s disease will continue without interruption. Under this redefined alliance, which resolves a previously disclosed dispute, Pfizer and Eisai will continue to co-promote Aricept in the U.S., Japan and key markets in Europe, and Pfizer will continue to have an exclusive license to sell Aricept in the other countries where it has rights. Pfizer will maintain its rights in all countries where it currently commercializes Aricept until July 2022, with the exception of Japan. Pfizer will now return the rights to Aricept in Japan, to Eisai on December 31, 2012.

    Pfizer and Eisai have also entered into a new agreement effective today to co-promote Lyrica in Japan. Lyrica is under regulatory review in Japan, and assuming approval is granted, this agreement will continue in force until July 2022.

    “Our continued partnership with Eisai is a testament to Pfizer’s commitment to help patients suffering from Alzheimer’s disease,” said Jeff Kindler, Pfizer Chairman and Chief Executive Officer. “In addition, we look forward to forging a new alliance with Eisai to help treat neuropathic pain with our co-promotion of Lyrica in Japan following regulatory approval.”

    Pfizer Inc: Working together for a healthier world™

    Founded in 1849, Pfizer is the world's premier biopharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality health care and health system support. At Pfizer, colleagues in more than 90 countries work every day to help people stay happier and healthier longer and to reduce the human and economic burden of disease worldwide.

     

     

    Pfizer Inc
    Joan Campion, 212-733-2798

     

     

    Product Pipeline

    Learn about specific ways our research is leading to medicines and vaccines that will benefit patients around the world.

    Corporate Fact Sheet

    For more than 170 years, Pfizer has worked to make a difference for all who rely on us.

    Coronavirus Resources

    Learn about SARS-CoV-2, the coronavirus that causes COVID-19, what you can do to stay safe and prevent the spread, and our scientific efforts to help bring an end to the current global health crisis.

    Pfizer Logo

    Our logo is shorthand for everything Pfizer represents: an image that is instantly identifiable to our colleagues, patients, the external scientific community, and the public.

    Executive Leadership

    Meet the executive leadership team, our senior-most leadership and decision-making management body who focus on major financial, strategic, and operational decisions for the entire company.